Approval on a knife edge

Nature Biotechnology

Volumn 30, Issue 1, 2012, Pages 26-29

  Eisenstein, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 [2 [4 (3 BENZYLOXYPHENYLTHIO) 2 CHLOROPHENYL]ETHYL] 1,3 PROPANEDIOL; ATACICEPT; BELIMUMAB; BLISIBIMOD; CYCLOPHOSPHAMIDE; CYOXAN; EPRATUZUMAB; FORIGERIMOD; LAQUINIMOD; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TABALUMAB; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; STANDARD OF CARE;

EID: 84855561922     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2084     Document Type: Article

References (7)

1. Stohl, W. & Hilbert, D.M. Nat. Biotechnol. 30, 69-77 (2012).
2. Petri, M. et al. Arthritis Rheum. 58, 2453-2459 (2008).
3. Anonymous. Guidance for Industry: Systemic Lupus Erythematosus-Developing Medical Products for Treatment (FDA, 2010). 〈http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf〉
4. Wallace, D.J. et al. Arthritis Rheum. 61, 1168-1178 (2009).
5. Navarra, S.V. et al. Lancet 377, 721-731 (2011).
6. F urie, R. et al. Arthritis Rheum. 62, S606 (2010).
7. Mount, G.R. & Gilliland, W.R. Clin. Pharmacol. Ther. 83, 167-171 (2008).